Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 supplementary data 2 supplementary data 3 supplementary data 4 supplementary data 5 appendix a supplementary data to this article can be found online at https://doi org/10 1016/j euros2023 02 014 ."

"

 Financial disclosures: Shahrokh F. Shariat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Philippe E. Spiess serves as a vice-chair of the National Comprehensive Cancer Network guidelines panel for bladder and penile cancer. Maximilian Pallauf has received a research grant from the Austrian Urological Association, support for attending the Austrian Urological Association yearly meeting, speaker honoraria from Astellas, Janssen, and MedMedia, and an honorarium from Spectra for attending an advisory board; he was a board member for the Austrian Urological Association from 2018 to 2021. Shahrokh F. Shariat has received honoraria from Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, and Takeda; has a consulting or advisory role for Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, and Takeda; and participates in speaker bureaus for Astellas, AstraZeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, and Takeda. The remaining authors have nothing to disclose. Financial disclosures:"

"

Financial disclosures: Shahrokh F. Shariat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Philippe E. Spiess serves as a vice-chair of the National Comprehensive Cancer Network guidelines panel for bladder and penile cancer. Maximilian Pallauf has received a research grant from the Austrian Urological Association, support for attending the Austrian Urological Association yearly meeting, speaker honoraria from Astellas, Janssen, and MedMedia, and an honorarium from Spectra for attending an advisory board; he was a board member for the Austrian Urological Association from 2018 to 2021. Shahrokh F. Shariat has received honoraria from Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, and Takeda; has a consulting or advisory role for Astellas, AstraZeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, and Takeda; and participates in speaker bureaus for Astellas, AstraZeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, and Takeda. The remaining authors have nothing to disclose. 

Funding/Support and role of the sponsor: None."